Referring to the MUC1 low subpopulation, disease free survival was significantly improved in patients treated with gemcitabine compared to those of the observation only group (HR for DFS: 0.58; 95% CI 0.40 to 0.85, p = .004)….In the observation group, we found favorable prognostic effects of low MUC1 expression (HR for DFS: 0.55; 95% CI 0.29 to 1.04, p = .062; HR for OS: 0.35, 95% CI 0.18 to 0.68, p = .001) as well as a strong trend for improved survival in the gemcitabine group (HR for DFS: 0.48; 95% CI 0.24 to 0.96, p = .041; HR for OS: 0.56, 95% CI 0.28 to 1.11, p = .093)...